The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.
Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...
New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.
Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.
More patients receiving obinutuzumab vs placebo had primary end point of SLE Responder Index 4. HealthDay News — For patients with systemic lupus erythematosus (SLE), obinutuzumab, a glycoengineered ...
Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...
Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...
Existing evidence suggests genetics, environmental factors, and exposure to specific chemicals—such as those in cigarettes—can all increase a person’s risk of systemic lupus erythematosus. Systemic ...
Systemic lupus erythematosus (SLE) is the most common form of lupus — it’s the type that 7 in 10 people with lupus have. It's what most people mean when they say "lupus." Experts don’t know what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results